Rationale and Design of GnG-Trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-Blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AMLSonia Jaramillo, Richard F. Schlenk, Johannes Krisam et al.|Research Square|2021Cited by 0
Tandem Duplications of the <i>UBTF</i> gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor OutcomeJulia-Annabell Georgi, Christian Thiede, Christoph Röllig et al.|Blood|2022Cited by 0